CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters | Zendy

Albert Minga | Zendy; Charlotte Lewden | Zendy; Delphine Gabillard | Zendy; Germain I Bomisso | Zendy; Thomas-d’Aquin Toni | Zendy; Arlette Emième | Zendy; Vincent Yapo | Zendy; André Inwoley | Zendy; Roger Salamon | Zendy; Xavier Anglaret | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

CD4 cell eligibility thresholds: an analysis of the time to antiretroviral treatment in HIV-1 seroconverters

Author(s) -

Albert Minga,

Charlotte Lewden,

Delphine Gabillard,

Germain I Bomisso,

Thomas-d’Aquin Toni,

Arlette Emième,

Vincent Yapo,

André Inwoley,

Roger Salamon,

Xavier Anglaret

Publication year - 2011

Publication title -

aids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.195

H-Index - 216

eISSN - 1473-5571

pISSN - 0269-9370

DOI - 10.1097/qad.0b013e32834625d3

Subject(s) - seroconversion , cohort , medicine , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , cohort study , antiretroviral treatment , virology , demography , viral load , sociology

WHO recommends initiating combination antiretroviral treatment at the minimal CD4 cell threshold of 350 cells/μl. In sub-Saharan Africa, the time for a recently infected patient to reach this threshold is unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research